Collado Argimiro, Gómez-Ferrer Alvaro, Rubio-Briones José, Bonillo Miguel Angel, Iborra Inmaculada, Solsona Eduardo
Servicio de Urología, Instituto Valenciano de Oncología, 46009 Valencia, España.
Arch Esp Urol. 2009 Dec;62(10):851-9. doi: 10.4321/s0004-06142009001000010.
Stress urinary incontinence alter radical prostatectomy is one of the most worrisome sequelae for the patient and urologist. The aim of this paper is to evaluate the indications of the suburethral mesh Invance, giving details on our preoperative evaluation and indication, surgical technique, and the correlation between preoperative findings and functional results.
Between February 2006 and January 2009 27 patients underwent surgery. All of them had more than one year of follow up after prostatectomy, urodynamic study and preoperative cystoscopy. Continence was evaluated by the number of pads/day and the ICIQ-UI SF questionnaire. Through a perineal incision three titanium screws with a polipropylene suture were inserted in each ischiopubic rami, and a silicon/polipropylene mesh (Invance) is affixed to them, compressing the bulbar urethra. Patients were divided into two groups: good prognosis (1-2 pads/day without urodynamic anomalies in the filling phase) and bad prognosis (3 pads/day, history of radiotherapy or bladder neck incision, and urodynamic anomalies). Cure was defined as a patient not needing pads, and improvement was defined as decrease in the number of pads per day.
Median follow up after Invance was 18 months (4-38). Nine patients used one pad/day, 10 used two, and eight used three pads /day. Six cases had underwent previous bladder neck incision and three radiotherapy. Globally, 20 patients (74% ) were cured and five (19% ) had improved. Cure rate was 100% in the good prognosis group and 61% in the bad prognosis group (p=0.03). No intraoperative complications were registered. During the immediate postoperative period,one patient required cystostomy tube for 10 days. Seven patients (26% ) presented perineal discomfort; neither de novo urgency nor urethral erosion nor sling explants due to infection were registered.
Invance is a safe technique that guarantees a high continence rate in selected patients. It is a reproducible operation and, with a midterm follow up, no loss of continence has been observed, and the risk of urethral erosion is null in our experience. Patients with mild-moderate incontinence, without urodynamic anomalies nor previous radiotherapy are the ideal candidates.
前列腺癌根治术后压力性尿失禁是患者和泌尿外科医生最担心的后遗症之一。本文旨在评估尿道下网状物Invance的适应证,详细介绍我们的术前评估和适应证、手术技术以及术前检查结果与功能结果之间的相关性。
2006年2月至2009年1月期间,27例患者接受了手术。所有患者在前列腺切除术后均进行了一年以上的随访、尿动力学研究和术前膀胱镜检查。通过每天使用的尿垫数量和ICIQ-UI SF问卷评估尿失禁情况。经会阴切口,在每侧耻骨支上插入三个带有聚丙烯缝线的钛螺钉,并将硅/聚丙烯网状物(Invance)固定在上面,压迫球部尿道。患者分为两组:预后良好(每天使用1 - 2个尿垫,充盈期无尿动力学异常)和预后不良(每天使用3个尿垫、有放疗史或膀胱颈切开史以及尿动力学异常)。治愈定义为患者不再需要使用尿垫,改善定义为每天使用尿垫数量减少。
Invance术后中位随访时间为18个月(4 - 38个月)。9例患者每天使用1个尿垫,10例使用2个,8例使用3个尿垫。6例患者曾接受过膀胱颈切开术,3例接受过放疗。总体而言,20例患者(74%)治愈,5例(19%)有所改善。预后良好组的治愈率为100%,预后不良组为61%(p = 0.03)。术中无并发症记录。术后即刻,1例患者需要留置膀胱造瘘管10天。7例患者(26%)出现会阴部不适;未出现新发尿急、尿道侵蚀或因感染导致的吊带取出情况。
Invance是一种安全的技术,可确保选定患者的高控尿率。这是一种可重复的手术,中期随访未观察到控尿能力丧失,根据我们的经验,尿道侵蚀风险为零。轻度至中度尿失禁、无尿动力学异常且无放疗史的患者是理想的候选者。